After recent publication in Parkinsonism and Related Disorders, detailed 6-month data on the first three patients will be presented this week at the 30^th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025), taking place in New York from May 7-10.  Aspen Neuroscience Medical Director Avram Fraint, M.D., M.S. will present "Safety, tolerability, and efficacy of intracranial delivery of autologous iPSC-derived dopaminergic precursors in moderate to advanced Parkinson's disease" on Saturday, May 10 during the IAPRD Guided Poster session.

"Parkinson's disease is the second most common neurodegenerative disorder. By the time of diagnosis, most people with Parkinson's have lost the majority of their dopaminergic neurons, leading to progressive loss of motor and non-motor function," said Dr. Fraint. "To date, data from the first three patients in the ASPIRO study show that precision delivery of personalized DANPCs is safe and well-tolerated."

"In this first-of-its-kind study, we are seeing clinician-reported and patient-reported improvements as well as a strong safety and tolerability profile at six months. Importantly, ANPD001 has the unique advantage of not requiring immunosuppression," said Edward Wirth III, MD, PhD, Chief Medical Officer of Aspen Neuroscience.

"We are very encouraged by the ASPIRO study results to date. With more than one million people currently living with Parkinson's disease in the U.S. alone, these data are promising for the Parkinson's community, and for the autologous cell therapy field," said Damien McDevitt, PhD, president and CEO of Aspen Neuroscience.